Barclays analyst Peter Lawson maintained a Buy rating on Springworks Therapeutics (SWTX – Research Report) today and set a price target of ...
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
In a report released today, Tara Bancroft from TD Cowen maintained a Buy rating on Mersana Therapeutics (MRSN – Research Report). The company’s ...
Check out the Casey Jones & the Junkyard Jam DLC Launch Trailer for TMNT: Splintered Fate, an action roguelike developed by Super Evil Megacorp. Players can now access the Casey Jones & the Junkyard ...
Casey Jones is making an appearance. Check out the latest Teenage Mutant Ninja Turtles: Splintered Fate trailer to see what ...
Yet again, the saga of the U.S. TikTok ban has entered a new chapter. After a fast-tracked Supreme Court decision upheld the law mandating that U.S. operations either be severed from Chinese ...
BOSTON, Jan. 27, 2025 /PRNewswire/ -- Averna Therapeutics, Inc. ("Averna"; formerly known as Exsilio Therapeutics, Inc.), a biotechnology company developing genomic medicines that insert ...
The latest trading session saw Viking Therapeutics, Inc. (VKTX) ending at $32.87, denoting a +0.67% adjustment from its last day's close. The stock's performance was behind the S&P 500's daily ...
NASDAQ:FATE opened at $1.32 on Wednesday. Fate Therapeutics has a 12-month low of $1.04 and a 12-month high of $8.83. The stock’s fifty day simple moving average is $1.98 and its 200-day simple ...
Dr. Gehchan brings decades of successful late-stage clinical development and commercial experience to role, further enhancing Kyverna's senior leadership team to execute Company's next wave of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback